Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Angel Investments in Europe and Recent Developments in Crowdfunding
Applegate, Lynda M.; Dessain, Vincent; Billaud, Emilie; Beyersdorfer, DanielaCaso HBS-814047-EIniciativa emprendedoraThis technical note provides information on the evolution and current state of angel investing in Europe. The note first describes the role and types of angel investors, focusing on their investment preferences and practices. It then details the new trends in the market, including the development of policy tools and the proliferation of incubators/accelerators to support angel investors. Finally, the note explores salient issues in angel investin...Desde 8,20 €
-
Go Beyond Investing
Applegate, Lynda M.; Dessain, Vincent; Billaud, Emilie; Beyersdorfer, DanielaCaso HBS-814046-EIniciativa emprendedoraIn 2013, Brigitte Baumann, founder of the Pan-European angel investing provider Go Beyond Investing, reflected on the evolution of her venture and the way forward. Her company, which offered deal flow and training to novice and experienced angel investors and ran investor groups in several European countries, had reached a critical size, and Baumann needed to make a strategic decision to ensure its future growth in an industry that was undergoing...Desde 8,20 €
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCaso HBS-313069-EDirección estratégicaThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Desde 8,20 €
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCaso HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Desde 8,20 €
-
Ilva Steel Taranto: Providing and Polluting (C)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCaso HBS-314059-EDesde 5,74 €
-
BASF: Co-Creating Innovation (B)
Rangan, V. Kasturi; Billaud, Emilie; Dessain, VincentCaso HBS-517074-EMarketingSupplement to case 517073.Desde 5,74 €
-
Poles apart on PZU (C)
Gino, Francesca; Dessain, Vincent; Misztal, Karol; Khayyat, MichaelCaso HBS-912015-EAfter a decade-long dispute with the Polish State Treasury, in October 2009 the Dutch insurer Eureko agreed to exit PZU in exchange for compensation. Who was the biggest beneficiary of the settlement: Eureko, the Treasury, or PZU itself?Desde 5,74 €
-
Ilva Steel Taranto: Providing and Polluting (B)
Goldberg, Lena G.; Dessain, Vincent; Pesce, Ottavia; Misztal, KarolCaso HBS-314058-EDesde 5,74 €
-
Veolia: Resourcing the World
Ahuja, Gautam; Khanna, Tarun; Maslauskaite, Kristina; Dessain, VincentCaso HBS-717505-EDirección estratégicaA global environmental service provider goes through major changes to offer integrated solutions and reach out to new countries.Desde 8,20 €
-
Poles apart on PZU (B)
Gino, Francesca; Dessain, Vincent; Misztal, Karol; Khayyat, MichaelCaso HBS-912014-EIn September 2008, the Polish State Treasury and the Dutch insurer Eureko were wondering if they were ready for reaching an amicable solution on PZU. If so, for how much and under what conditions should they settle so that they, as well as PZU, are satisfied? If not, what other potential alternatives might exist?Desde 5,74 €